LPA and MMP12

Number of citations of the paper that reports this interaction (PubMedID 10187779)
4

Data Source:
HPRD (in vitro)

		LPA	MMP12
Description		lipoprotein(a)	matrix metallopeptidase 12
Image		No pdb structure
GO Annotations	Cellular Component	Extracellular Region Plasma Lipoprotein Particle	Extracellular Region Extracellular Space Nucleus Cytoplasm Extracellular Matrix
	Molecular Function	Fibronectin Binding Serine-type Endopeptidase Activity Endopeptidase Inhibitor Activity Protein Binding Heparin Binding Apolipoprotein Binding	Core Promoter Binding Endopeptidase Activity Metalloendopeptidase Activity Calcium Ion Binding Collagen Binding Zinc Ion Binding Sequence-specific DNA Binding
	Biological Process	Proteolysis Lipid Metabolic Process Lipid Transport Blood Circulation Negative Regulation Of Endopeptidase Activity Low-density Lipoprotein Particle Remodeling	Negative Regulation Of Transcription By RNA Polymerase II Proteolysis Protein Import Into Nucleus Extracellular Matrix Disassembly Extracellular Matrix Organization Collagen Catabolic Process Wound Healing, Spreading Of Epidermal Cells Positive Regulation Of Transcription By RNA Polymerase II Regulation Of Defense Response To Virus By Host Positive Regulation Of Epithelial Cell Proliferation Involved In Wound Healing Elastin Catabolic Process Negative Regulation Of Type I Interferon-mediated Signaling Pathway Positive Regulation Of Type I Interferon-mediated Signaling Pathway Cellular Response To Virus Positive Regulation Of Interferon-alpha Secretion Response To Amyloid-beta Negative Regulation Of Endothelial Cell-matrix Adhesion Via Fibronectin
Pathways			Collagen degradation Degradation of the extracellular matrix Degradation of the extracellular matrix
Drugs			Acetohydroxamic Acid Marimastat CP-271485 PF-00356231 Batimastat 2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4'-Ethoxy-1,1'-Biphenyl-4-Yl)-4-Oxobutanoic Acid AE-941 (1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE N-(biphenyl-4-ylsulfonyl)-D-leucine N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide 2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide N-oxo-2-(phenylsulfonylamino)ethanamide N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID N-[(4-methoxyphenyl)sulfonyl]-D-alanine
Diseases
GWAS		Aortic valve stenosis ( 29511194) Aortic-valve calcification ( 23388002) Blood protein levels ( 28240269) Body mass index ( 26426971) Body mass index (age>50) ( 26426971) Body mass index x sex x age interaction (4df test) ( 26426971) Cholesterol, total ( 24097068 28270201 25961943 20686565) Coronary artery disease ( 29212778 24262325 30104761 26343387 28714974) Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) ( 28714975) Coronary artery disease in diabetes ( 30003307) Coronary artery disease or ischemic stroke ( 24262325) Coronary artery disease or large artery stroke ( 24262325) Coronary heart disease ( 19198611 21378990) End stage renal disease x APOL1 genotype interaction ( 29885931) HDL cholesterol ( 25961943 20686565) HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Heart failure ( 31919418) Ischemic stroke (large artery atherosclerosis) ( 29531354) LDL cholesterol ( 24097068 30275531 25961943 20686565) LDL cholesterol levels in current drinkers ( 30698716) LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Lipid or lipoprotein levels ( 23696881) Lipoprotein (a) levels ( 26377243 30108283 28512139) Lipoprotein (a) levels in coronary artery disease (percutaneous coronary intervention) ( 31186284) Lipoprotein phospholipase A2 activity in cardiovascular disease ( 28753643) Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms ( 28512139) Lipoprotein-associated phospholipase A2 activity change in response to statin therapy ( 23118302) Lp (a) levels ( 21900290 19124843) Medication use (agents acting on the renin-angiotensin system) ( 31015401) Medication use (antithrombotic agents) ( 31015401) Medication use (beta blocking agents) ( 31015401) Medication use (HMG CoA reductase inhibitors) ( 31015401) Medication use (salicylic acid and derivatives) ( 31015401) Medication use (vasodilators used in cardiac diseases) ( 31015401) Metabolic syndrome ( 31589552) Metabolite levels (lipoprotein measures) ( 27005778) Minimum ankleâ€“brachial index ( 31285632) Monocyte early outgrowth colony forming units ( 21493818) Myocardial infarction ( 26343387) Parental lifespan ( 29030599) Parental longevity (both parents in top 10%) ( 29227965) Parental longevity (combined parental age at death) ( 29227965) Parental longevity (combined parental attained age, Martingale residuals) ( 29227965) Parental longevity (father's age at death) ( 31484785 29227965) Parental longevity (father's attained age) ( 29227965) Parental longevity (mother's age at death or mother's attained age) ( 31484785) Parental longevity (mother's age at death) ( 29227965) Parental longevity (mother's attained age) ( 29227965) Peripheral artery disease ( 31285632) Plasma plasminogen levels ( 25208887) Protein quantitative trait loci ( 18464913) Response to statin therapy ( 22368281) Response to statins (LDL cholesterol change) ( 25350695 22331829) Total cholesterol levels ( 28334899 30275531) Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Triglycerides ( 30275531 25961943)	Alzheimer's disease ( 22832961) Blood protein levels ( 30072576 29875488 28240269) Blood protein levels in cardiovascular risk ( 28369058) Cerebrospinal fluid levels of Alzheimer's disease-related proteins ( 25340798) Chronic obstructive pulmonary disease (severe) ( 24621683) Emphysema imaging phenotypes ( 26030696) Ischemic stroke ( 29531354) Ischemic stroke (large artery atherosclerosis) ( 29531354) Local histogram emphysema pattern ( 25006744) Peanut allergy ( 29030101) Post bronchodilator FEV1 ( 26634245) Post bronchodilator FEV1/FVC ratio ( 26634245) Post bronchodilator FEV1/FVC ratio in COPD ( 26634245) Stroke ( 29531354)
Interacting Genes		9 interacting genes: APOH CANX CELA1 ELANE FBLN5 FGB FN1 LRP2 MMP12	5 interacting genes: APP F12 LPA PLAUR TFPI
Entrez ID		4018	4321
HPRD ID		01063	03027
Ensembl ID		ENSG00000198670	ENSG00000262406
Uniprot IDs			P39900
PDB IDs			1JIZ 1JK3 1OS2 1OS9 1RMZ 1ROS 1UTT 1UTZ 1Y93 1YCM 1Z3J 2HU6 2JXY 2K2G 2K9C 2KRJ 2MLR 2MLS 2N8R 2OXU 2OXW 2OXZ 2POJ 2W0D 2WO8 2WO9 2WOA 2Z2D 3BA0 3EHX 3EHY 3F15 3F16 3F17 3F18 3F19 3F1A 3LIK 3LIL 3LIR 3LJG 3LK8 3LKA 3N2U 3N2V 3NX7 3RTS 3RTT 3TS4 3TSK 3UVC 4EFS 4GQL 4GR0 4GR3 4GR8 4GUY 4H30 4H49 4H76 4H84 4I03 4IJO 5CXA 5CZM 5D2B 5D3C 5I0L 5I2Z 5I3M 5I43 5I4O 5L79 5L7F 5LAB 5N5J 5N5K 6EKN 6ELA 6ENM 6EOX
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?